Top Markets
Coin of the day
Molecular Pharmacology (USA), Ltd. Molecular Pharmacology (USA), Ltd.

Molecular Pharmacology (USA), Ltd.

MLPH
Rang in aandelen #39112
As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is... As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and market a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.
Aandeelprijs
$0.0322
Laatst gesynchroniseerd: 2026-08-11
Marktkapitalisatie
$643.71K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
544.00%
Land
AU
Handel Molecular Pharmacology (USA), Ltd. (MLPH)

Categorie

EPS voor Molecular Pharmacology (USA), Ltd. (MLPH)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Molecular Pharmacology (USA), Ltd. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Molecular Pharmacology (USA), Ltd. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten